Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 19/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorescein SCHEMBL1434704 | 0.89 | STING1 (0.65) | STING1 | |
| SCHEMBL19954144 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21498373 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21470181 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL12634565 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL24467522 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17974376 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL14980248 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL12671632 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL52166 | 0.81 | STING1 (1.00) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270444-A1 | 1,7-Naphthyridines | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | disclosed |
| EP-1866305-A1 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007107499-A1 | QUINOLINE DERIVATIVES USEFUL AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1812434-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006097340-A1 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006089689-A1 | 2-QUINOLONE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASES | GLAXO GROUP LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| EP-1673345-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006053784-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
| WO-2005030725-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | STING1 1392/4885PDE3B 3/4885PDE3A 5/4885 |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | STING1 1616/4885PDE3B 3/4885PDE3A 5/4885 |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | PDE4A, PDE3B, PDE4B | STING1 3398/4885PDE3B 2/4885PDE3A 5/4885 |
| US-20090270444-A1 | 1,7-Naphthyridines | CYP2F1, CYP2S1, CYP1A1 | STING1 4135/4885PDE3B 1375/4885PDE3A 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.